الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 88 |  |  |
| | | from | 88 | | |
Abstract
Ureteral stents are a convenient means of drainage for the upper urinary tract and will continue to be an essential tool in urology practice. However, their use is not devoid of side effects and they cause a wide range of urinary symptoms that affect the patients’ general health and work performance as dysuria, urgency and frequency, hematuria, loin pain, suprapubic pain, urethral and perineal pain.
There has been great interest in this field of research, as marked by introduction of new biomaterials, coatings, and ureteral stent designs, also pharmacologic management are under trial to help in reducing this stent-related morbidity.
In our study we tried to assess the efficacy of Tamsulosin .4 mg daily, Solifenacin 5 mg daily and a combination of both in relieving SRSs and found that :-
Irritative LUTS are better controlled with solifenacin than tamsulosin.
Flank pain is better improved with tamsulosin while suprapubic pain is better improved with solifenacin.
Combined therapy group has superior effect to monotherapy in relieving ureteral stent-related symptoms.
Work performance and sexual problems are better preserved in medication therapy groups.
No general improvement as regarding of hematuria and UTI in all groups.
Tamsulosin and solifenacin are well tolerated drugs with no serious adverse events.
We recommend the following instructions to manage the associated stent related symptoms:-
(1) Discussion in clinic regarding stent symptoms before surgery and risk versus benefit ratio with them.
(2) Always ensure there is an indication for initial stent placement.
(3) The indwelling time should be minimized.
(4) The combination of tamsulosin and solifenacin could be given.
(5) Match the length of stent to patient height as several studies have shown that inappropriate stent length would worsen LUTS.